Sysmex Corporation (6869)

Currency in JPY
2,128.0
-31.5(-1.46%)
Closed·
6869 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2,100.02,155.0
52 wk Range
1,246.02,227.5
Key Statistics
Bid/Ask
2,125.00 / 2,134.00
Prev. Close
2,159.5
Open
2,110
Day's Range
2,100-2,155
52 wk Range
1,246-2,227.5
Volume
1.93M
Average Volume (3m)
3M
1-Year Change
42.151%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6869 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2,203.6
Upside
+3.55%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Sysmex Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Analyst Ratings

8 Buy
6 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 2,203.6
(+3.55% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Goldman Sachs
Buy2,200.00+3.38%1,950.00Maintain20-10-2026
JPMorgan
Buy1,900.00-10.71%1,600.00Maintain25-09-2026
Nomura/Instinet
Hold1,800.00-15.41%1,400.00Maintain27-08-2026
Citi
Hold1,900.00-10.71%1,500.00Maintain20-08-2026
Goldman Sachs
Buy1,950.00-8.36%1,700.00Maintain10-08-2026

Sysmex Corporation Earnings Call Summary for Q2/2027

  • Sysmex Q2 FY2026 EPS of $15.30 beat estimates of $14.61; revenue of $142.15B topped forecast of $134.41B; shares fell 2.63% after-hours.
  • Americas drove growth with 16.5% local-currency gain; U.S. hematology replacement rate hit 99%, while China sales plunged 22.4% on cost controls.
  • Free cash flow improved to 34B yen; operating profit reached 33B yen despite 5.7B yen goodwill impairment in clinical chemistry segment.
  • Full-year guidance unchanged: 550B yen sales, 68.5B yen operating profit; China expected down 10% in H2 as pricing revisions continue.
  • Portfolio review ongoing, focusing on four core diagnostics areas and new growth in dementia diagnostics; medical robotics venture remains unprofitable.
Last Updated: 11-11-2026, 07:48 pm
Read Full Transcript

Earnings

Latest Release
10-11-2026
EPS / Forecast
15.30 / 14.61
Revenue / Forecast
142.15B / 134.41B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 55.82
Dividend Yield
1.85%
Industry Median 1.52%
Annualised payout
40.00
Paid unevenly
5-Years Growth
-5.85%
Growth Streak

6869 Income Statement

Compare 6869 to Peers and Sector

Metrics to compare
6869
Peers
Sector
Relationship
P/E Ratio
37.8x23.6x−0.2x
PEG Ratio
−1.49−0.790.00
Price/Book
2.7x2.5x2.6x
Price / LTM Sales
2.4x2.3x2.7x
Upside (Analyst Target)
3.4%14.4%72.2%
Fair Value Upside
Unlock12.8%12.4%Unlock

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers hematology, a major test routinely included in blood tests; Flow Cytometry (FCM) analyzes cell properties by irradiating individual cells with a laser and measuring the intensity of light scattering and fluorescence; urinalysis test checks for the presence of glucose, proteins, and blood in urine; clinical chemistry; hemostasis; immunochemistry; cancer gene testing; and antimicrobial susceptibility testing. The company also provides Caresphere, an ICT solution, which integrates and analyzes real time various data managed through testing instruments and clinical testing information systems, and supports the efficient operation of clinical laboratories; and involved in the medical robotics business. It serves products and services to medical institutions, clinical laboratories, animal hospitals, and research institutes. Sysmex Corporation has strategic alliance with Hologen to turn routine blood test data into clinical intelligence. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

Employees
10861
Market
Japan

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
176.14M29.25%372.62B
Other Institutional Investors
138.51M23.01%293.02B
Public Companies & Retail Investors
287.43M47.74%608.06B
Total
602.08M100.00%1.27T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Nakatani Foundation6.43%3,86,92,0008,18,52,926
Kobe Yamabuki Zaidan, General Foundation5.98%3,60,00,0007,61,58,000

FAQ

What Is the Sysmex (6869) Share Price Today?

The Sysmex share price today is 2,128.0.

What is the current Sysmex (6869) share price and day range?

As of 20-11-2026, the Sysmex share price is 2,128.0, with a previous close of 2,159.5. The share price has ranged from 2,100.0 to 2,155.0 today, while the 52-week range spans from 1,246.0 to 2,227.5.

What Is the Sysmex Market Cap?

As of today, Sysmex market cap is 1.3T.

Does Sysmex Pay Dividends? What's The Current Dividend Yield?

The Sysmex dividend yield is 1.9%%.

What Is the Sysmex (6869) Share Price Target?

The average 12-month share price target for Sysmex is 2,203.6, with a high estimate of 3300 and a low estimate of 1500. 8 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +3.55% Upside potential.

What Is Sysmex's Earnings Per Share (TTM)?

The Sysmex EPS (TTM) is 55.82.

When Is the Next Sysmex Earnings Date?

Sysmex will release its next earnings report on 11-02-2027.

From a Technical Analysis Perspective, Is 6869 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Stock Exchange Does Sysmex Trade On?

Sysmex is listed and trades on the Tokyo Stock Exchange.

What Is the Stock Symbol for Sysmex?

The stock symbol for Sysmex is "6869."

How Many Times Has Sysmex Stock Split?

Sysmex has split 4 times.

How Many Employees Does Sysmex Have?

Sysmex has 10861 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.